Quick Facts

• Condition Managed: Lipodystrophy in HIV-infected adults.
• Therapeutic Action: Aims to reduce excess abdominal fat (visceral adipose tissue).
• Intended Use: For the management of abnormal fat distribution associated with HIV infection.

Egrifta (tesamorelin) is a specialized medication indicated for the management of abnormal body composition in adult patients living with Human Immunodeficiency Virus (HIV) who have lipodystrophy. This condition is characterized by changes in fat distribution, specifically the accumulation of excess visceral abdominal fat (VAT).

The primary therapeutic function of Egrifta is the reduction of this excess abdominal fat. The treatment is associated with the decrease of visceral adipose tissue in the abdomen, which may help with body image perception in affected individuals.

It is important to understand that Egrifta is not intended for general weight loss management, as its effect is concentrated on visceral fat, and it is considered weight-neutral overall. Use is generally considered when other interventions, such as diet and exercise, have not adequately addressed the issue.

Egrifta (tesamorelin) is authorized for a specific, narrow patient population, as defined by regulatory documents. Use is restricted to adult patients aged 18 years and older who are HIV-infected and have lipodystrophy with excess visceral abdominal fat. It is not indicated for weight loss management or for use in patients without the specified comorbidity and condition.

Contraindications (Who Must Not Use)

Official labeling identifies several groups for whom Egrifta is contraindicated, meaning they must not use the medicine:

• Pregnant women (due to the potential for fetal harm).
• Patients with an active malignancy (newly diagnosed or recurrent).
• Patients with a disruption of the hypothalamic-pituitary axis (e.g., due to a pituitary tumor, surgery, or head trauma).
• Patients with a known hypersensitivity to tesamorelin or excipients (such as mannitol).

Age and Conditional Use Restrictions

Population Group	Regulatory Status
Pediatric patients (under 18)	Safety and effectiveness are not established; use is not recommended.
Geriatric patients (over 65)	No information is available on use in this age group.
Lactating mothers	Not recommended due to the risk of postnatal HIV-1 transmission and potential infant risk.

Patients with a history of treated and stable malignancy or those who develop glucose intolerance require careful evaluation and monitoring, and discontinuation must be considered if the underlying condition changes or if IGF-1 levels are persistently elevated.

Egrifta Interactions with other medicines and products

Egrifta (tesamorelin) has documented interaction patterns that are defined by its influence on specific metabolic enzymes and the resultant impact on co-administered medicines. The drug is classified as having the potential for clinically significant interactions based on its effect on the enzyme 11-beta-hydroxysteroid dehydrogenase type-1 (11ß-HSD1).

Interacting Substance Category	Interaction Mechanism and Outcome
Corticosteroid Prodrugs	Inhibition of 11ß-HSD1 causes decreased concentrations of the active metabolite for prodrugs like cortisone and prednisone, potentially leading to loss of efficacy.
Ritonavir	Co-administration resulted in a minor decrease (9–11%) in the drug’s total exposure (AUC) and peak concentration (Cmax).
Simvastatin	Regulatory studies documented no significant impact on the pharmacokinetic profile of simvastatin.

For patients with previously diagnosed hypoadrenalism who receive glucocorticoid replacement therapy, this enzyme-mediated interaction results in the requirement for potential dose consideration of the glucocorticoid. No drug–drug combinations are formally listed as contraindicated in regulatory labeling. Furthermore, regulatory documents state no known interactions with food or drinks, and no mandatory timing separation rules are required. The interaction status with alcohol is documented as unknown in official sources.

How Egrifta Works

Egrifta (tesamorelin) functions as a synthetic analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Its mechanism involves engaging the body's native neuroendocrine axis to modulate metabolic processes, including lipid catabolism.

---

Agonist Action at the Pituitary Gland

It selectively binds to and stimulates the GHRH receptors located on the somatotroph cells of the anterior pituitary gland. The binding event engages receptor-mediated signaling, thereby initiating a hormonal cascade.

---

Cascade of GH-IGF-1 Modulation

Stimulation of GHRH receptors triggers the pituitary to synthesize and release its own endogenous Growth Hormone (GH) in a pulsatile manner. This increase in circulating GH then leads to an upstream effect on the liver and peripheral tissues, promoting the subsequent production of Insulin-like Growth Factor-1 (IGF-1). This action influences the activity of targeted neuroendocrine pathways.

---

System-Level Lipolytic Effects

The released GH binds to specific receptors on target cells, including adipocytes (fat cells). This binding promotes the known lipolytic (fat-breaking) and anabolic properties associated with GH, resulting in the altered catabolism of lipids.

Administration Overview

Egrifta is administered via subcutaneous injection, typically into the abdominal area. The process involves reconstituting a lyophilized powder with a provided diluent before use. It is important to rotate injection sites regularly to maintain skin health and avoid areas with scar tissue, redness, or irritation.

Preparation and Handling

The medication requires careful preparation to ensure the solution is clear and properly mixed. Before administration, the vial should be inspected for any particulate matter or discoloration. Only the specific diluent provided by the manufacturer should be used for reconstitution. Once the powder and liquid are combined, the vial is usually swirled gently rather than shaken to prevent foaming.

Storage Requirements

Proper storage is necessary to maintain the stability of the medication. The sterile water used for reconstitution and the medication vials themselves should be kept according to the temperature specifications provided by the pharmacy. Any prepared solution that is not used immediately should be handled according to specific disposal protocols.

Injection Site Care

Maintaining a clean injection site is a standard part of the administration process. This typically involves cleaning the skin with an alcohol swab and allowing it to dry completely. After the injection, the site should not be rubbed. Used needles and syringes must be placed in a puncture-resistant sharps container to ensure safe disposal.

Research evidence / Overview of studies for Egrifta

Evidence for Reducing Excess Abdominal Fat in HIV-Associated Lipodystrophy

This section will summarize the structure of the main research studies, including the two primary placebo-controlled randomized trials, which evaluated the use of Egrifta in adults with HIV to evaluate the measured change in the accumulation of visceral abdominal fat (VAT). The discussion will focus on the study designs, the patient populations included, and the primary methods researchers used to measure changes in VAT.

Research has explored the use of Egrifta in adults with Human Immunodeficiency Virus (HIV) who experience lipodystrophy. The core evidence was derived from two large-scale, short-term, randomized controlled trials (RCTs). In these studies, adult patients on stable HIV therapy were randomly assigned to receive either Egrifta or an inactive substance (placebo). The core research examined changes in the measured area of visceral abdominal fat over defined time intervals.

Outcomes Evaluated in Clinical Trials

The studies monitored the VAT levels using specialized imaging techniques, primarily computed tomography (CT) scans, at the beginning and the end of the short-term study period, which was typically 26 weeks. Findings describe patterns observed in the measured VAT area, noting the difference in measurements recorded between the group receiving Egrifta and the group receiving placebo. Research also examined changes in certain metabolic factors, such as blood cholesterol and triglyceride levels, which are measurements of physiological parameters.

Long-Term Studies and Durability of Effect

Research also examined what happened when the medicine was stopped after the initial study period. These findings indicate that the measured VAT levels in these patients began to revert toward the levels recorded before treatment started. Research describes that the observed change was dependent on continuous use of the medicine.

Understanding Research Gaps and Uncertainties

While research describes short-term and intermediate-term patterns related to VAT measurements, long-term effects are not fully established. The initial trials were not designed to monitor major health outcomes over many years, such as the potential impact on heart disease or other serious conditions. For this reason, post-marketing studies were required for continued observation over extended periods.

Key Studies & References

1. Clinical Review Report: Tesamorelin (Egrifta) – Clinical Trials Results and Efficacy Summary
2. Tesamorelin: A Clinically Proven Peptide for Visceral Fat — What Science Tells Us About Anti-Aging, & Wellness - Evergreen Institute

Common questions about Egrifta (FAQ)

Q: Is Egrifta the same kind of medication as other growth hormone drugs?

A: Official product information classifies Egrifta as a Growth Hormone-Releasing Factor (GHRF) analog. This means the medicine works by stimulating the body's own pituitary gland to release its endogenous growth hormone. It is therefore described as different from direct growth hormone replacement therapies.

Q: How does Egrifta fit into a treatment plan for HIV-related lipodystrophy?

A: Egrifta is an authorized treatment intended for the reduction of excess visceral abdominal fat in certain adult patients with HIV-associated lipodystrophy. Regulatory-cited guidance suggests that, like other treatments for this condition, it is used as an option alongside other management strategies, such as dietary modifications and exercise.

Q: What is the difference between Egrifta and Egrifta SV?

A: Egrifta is available in two formulations, Egrifta SV and Egrifta WR. The difference lies in the stability and preparation of the medicine once mixed. For instance, Egrifta SV is authorized for immediate use after mixing, while the Egrifta WR formulation is designed to provide doses from one vial for up to seven days.

Q: Does Egrifta treatment stop when fat reduction goals are met?

A: Official documents state that continuation of therapy may be reassessed if a patient does not demonstrate a reduction in visceral abdominal fat (VAT) after an initial period of use. Since the long-term effects of elevated IGF-1 levels are not fully established, continuous monitoring is part of the treatment protocol.

Q: Can Egrifta interact with cholesterol-lowering medicines?

A: According to regulatory reviews, Egrifta has shown no significant impact on the specific cholesterol-lowering medicine simvastatin. Official documentation does not provide data on potential interactions with all other medications in this class (e.g., other statins or fibrates).

Q: What does 'Egrifta is a recombinant growth hormone-releasing factor' mean in plain language?

A: The term 'recombinant' indicates that the active ingredient, tesamorelin, is a synthetic peptide. This means the substance was created in a laboratory using biotechnology to closely mimic the structure and function of the body's natural Growth Hormone-Releasing Hormone (GHRH).

Q: Does Egrifta help with fat in other areas of the body besides the abdomen?

A: Egrifta is specifically authorized for the reduction of visceral abdominal fat (VAT), which is the deep, pathological accumulation of fat. The official indication does not include the reduction of fat located in other areas of the body, such as subcutaneous fat directly beneath the skin.

Q: What does the term 'lipodystrophy' mean in a simple way?

A: Official descriptions define HIV-associated lipodystrophy as a metabolic condition linked to fat redistribution, insulin resistance, and elevated blood lipids. This describes the abnormal fat distribution in the abdominal area that Egrifta is intended to address.

Q: What are the common misunderstandings about what Egrifta can do?

A: Official limitations included in the product information aim to clarify its intended use. For example, Egrifta is specifically not indicated for weight loss management as its effect is directed at a specific type of fat accumulation and it is not authorized for use in patients who do not have HIV-associated lipodystrophy.

Q: What are the concerns about using Egrifta with alcohol?

A: According to official regulatory sources, the potential interaction status between Egrifta and alcohol has not been established. This means that the impact of simultaneous use is not documented in the product labeling.

Q: How quickly does Egrifta start to work after the first dose?

A: Clinical trial data reviewed by regulators primarily measured the effect of Egrifta, which is the reduction in visceral abdominal fat, at 26 weeks. The official prescribing information does not contain data on the specific speed of the initial, short-term effect after the first dose.

Q: Do I need to change my diet while taking Egrifta?

A: While Egrifta itself is not a weight-loss drug, the official management of HIV-associated lipodystrophy often involves comprehensive care. Management guidelines suggest that GHRF analogs are used alongside established strategies such as regular exercise and dietary modifications.

Q: Why is Egrifta given as an injection instead of a pill?

A: Egrifta is a peptide (protein-like) molecule that is designed to act on the body's hormonal system. Due to its chemical structure, regulatory documentation confirms that the substance would likely be broken down by the digestive system if taken orally. Therefore, it is administered subcutaneously to facilitate proper absorption.

Q: Is Egrifta studied in both men and women?

A: Yes, the clinical development program included both men and women. The inclusion criteria used for the main clinical trials specified separate thresholds for men and women regarding measures of abdominal lipodystrophy to ensure a relevant study population was included.

Q: Is Egrifta considered a controlled substance?

A: Egrifta (tesamorelin) is a prescription-only medicine but is not classified as a controlled substance under the Controlled Substances Act (CSA) in the United States.

Q: Is there a maximum time a person can take Egrifta?

A: Regulatory guidance acknowledges that the long-term effects of Egrifta are still being monitored. The prescribing information suggests that continued use beyond one year may be an option if the patient is still receiving clinical benefit and does not experience significant adverse effects.

Q: Are there any reports of Egrifta causing mood changes?

A: Official adverse event reporting includes listings for nervous system disorders, such as headache and paresthesia (tingling/numbness). Additionally, less common psychological changes that have been reported include feelings like discouragement, irritability, and trouble concentrating.

Q: What are the research findings regarding Egrifta and quality of life?

A: In addition to measuring fat reduction, clinical trials evaluated patient-reported outcomes (PROs) related to body image and quality of life (QoL). The research findings related to overall QoL were mixed, but some results indicated statistically significant improvements in patient-reported distress regarding belly appearance.

Q: Are there known reports of Egrifta affecting eyesight?

A: General ocular adverse events are not commonly reported with this medicine. However, because Egrifta works by stimulating Growth Hormone and Insulin-like Growth Factor-1 (IGF-1), regulatory guidelines note that elevated IGF-1 levels are associated with the potential worsening of existing diabetic eye disease (retinopathy).

The storage and disposal of EGRIFTA (tesamorelin) must strictly follow the conditions defined in the official regulatory labeling.

Product Form	Storage Requirement	Shelf-Life Condition
Unreconstituted Powder & Diluent	Store at room temperature (20 C to 25 C / 68 F to 77 F) in the original carton.	Store until expiration date.
EGRIFTA SV Reconstituted	Must be used immediately; Do not refrigerate or freeze.	Discard if not used right away.
EGRIFTA WR Reconstituted	Store at room temperature (20 C to 25 C / 68 F to 77 F); Do not freeze.	Discard 7 days after mixing.

The vials must be protected from light. All components, including the diluent, must be stored out of the reach of children. Used needles, syringes, and vials must be immediately placed in an FDA-cleared sharps disposal container. These containers must not be thrown away in household trash; disposal must follow local, state, and national regulations.